drugset / Trial / NCT05698329

Effect of AIV007 by Periocular Administration in Subjects with Macular Edema Secondary to Neovascular Age-related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME)

NCT05698329

Phase 1 Active not recruiting 19 enrolled AiViva BioPharma, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

To determine safety, pharmacokinetics, and duration of effect of periocularly administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME).

Timeline

Start
2023-03-02
Primary completion
2025-03-03
Completion
2025-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject AIV007 Unknown Other